Cargando…

Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma

BACKGROUND: Antitumor immune response of programmed cell death ligand (PD-L1) has shown clinical value not only in Hodgkin lymphoma and EBV-associated lymphomas but also in EBV-negative diffuse large B cell lymphoma (DLBCL) of non-germinal center B cell-like (non-GCB) subtype. Signal transducer and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwon, Hyun Jung, Yang, Jeong Mi, Lee, Jeong-Ok, Lee, Jong Seok, Paik, Jin Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245852/ https://www.ncbi.nlm.nih.gov/pubmed/30458835 http://dx.doi.org/10.1186/s12967-018-1689-y

Ejemplares similares

Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma
por: Lee, Ki Rim, et al.
Publicado: (2022)

Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma
por: Yang, Jeong Mi, et al.
Publicado: (2018)

Bcl-6-dependent risk stratification by nuclear expression of Peli1 in diffuse large B-cell lymphoma
por: Lee, Ki Rim, et al.
Publicado: (2022)

Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma
por: Ahn, Hyein, et al.
Publicado: (2017)

PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications
por: Xing, Wei, et al.
Publicado: (2016)

Clinicopathological analysis of polyploid diffuse large B-cell lymphoma
por: Shimono, Joji, et al.
Publicado: (2018)

Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy
por: Lee, Seul, et al.
Publicado: (2017)

PD-L1 Expression Correlated with Clinicopathological Factors and Akt/Stat3 Pathway in Oral SCC
por: Geum, Dong-Ho, et al.
Publicado: (2022)

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
por: Lee, Ju-Han, et al.
Publicado: (2017)

Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients
por: Fei, Yue, et al.
Publicado: (2020)

The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis
por: Qiu, Liping, et al.
Publicado: (2019)

Clinicopathological and Prognostic Roles of STAT3 and Its Phosphorylation in Glioma
por: Liang, Bo, et al.
Publicado: (2020)

Clinicopathologic Analysis of Localized Nasal/Paranasal Diffuse Large B-Cell Lymphoma
por: Toda, Hiroko, et al.
Publicado: (2013)

Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP
por: Choi, Yong Won, et al.
Publicado: (2014)

Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
por: Park, Jeayeon, et al.
Publicado: (2023)

Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma
por: Kim, Dae Wook, et al.
Publicado: (2023)

Stroke Mimicking Encephalopathy as an Initial Manifestation of Diffuse Large B-Cell Lymphoma
por: Kim, Jeong-Min, et al.
Publicado: (2009)

Primary thyroid mucosa-associated lymphoid tissue lymphoma; a clinicopathological study of seven cases
por: Lee, Seung Chul, et al.
Publicado: (2011)

Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B‐cell lymphoma
por: Tian, Tian, et al.
Publicado: (2020)

Clinicopathological characteristics and treatment outcome in obese patients with diffuse large B-cell lymphoma
por: Wu, Yu-Ying, et al.
Publicado: (2020)

STAT-3 RNAscope Determination in Human Diffuse Large B-Cell Lymphoma()
por: Tamma, Roberto, et al.
Publicado: (2019)

MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status
por: Kim, Hyojin, et al.
Publicado: (2016)

IGH::CD274 (PD‐L1) rearrangement in diffuse large B cell lymphoma and its therapeutic implication
por: Wu, Xuemei, et al.
Publicado: (2023)

Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
por: Yi, Jun Ho, et al.
Publicado: (2023)

Prognostic and Clinicopathological Value of Survivin in Diffuse Large B-cell Lymphoma: A Meta-Analysis
por: Zhang, Ya, et al.
Publicado: (2015)

Correlation between Immunohistochemical Subtype and Clinicopathological Features in Patients with Diffuse Large B-cell Lymphoma
por: PATRASCU, ANA-MARIA, et al.
Publicado: (2017)

STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas
por: Pan, Yi-Ru, et al.
Publicado: (2018)

A Case of Cutaneous Epstein-Barr Virus-Associated Diffuse Large B-Cell Lymphoma in an Angioimmunoblastic T-Cell Lymphoma
por: Lee, Mi-Hye, et al.
Publicado: (2016)

Prognostic significance of STAT3 and phosphorylated STAT3 in human soft tissue tumors - a clinicopathological analysis
por: David, Diana, et al.
Publicado: (2011)

The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas
por: Garcia-Lacarte, Marcos, et al.
Publicado: (2021)

Prognostic impact of pretreatment skeletal muscle index and CONUT score in diffuse large B-cell Lymphoma
por: Go, Se-Il, et al.
Publicado: (2023)

EBV-positive diffuse large B-cell lymphoma of the elderly with aberrant expression of CD3 and TIA-1
por: Lee, Miji, et al.
Publicado: (2013)

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study
por: Yhim, Ho-Young, et al.
Publicado: (2010)

Clinicopathological analysis of primary intestinal diffuse large B‐cell lymphoma: Prognostic evaluation of CD5, PD‐L1, and Epstein‐Barr virus on tumor cells
por: Ishikawa, Eri, et al.
Publicado: (2018)

Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma
por: Hong, Junshik, et al.
Publicado: (2017)

Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma
por: Gu, Qianhui, et al.
Publicado: (2021)

Clinicopathological analysis of methotrexate‐associated lymphoproliferative disorders: Comparison of diffuse large B‐cell lymphoma and classical Hodgkin lymphoma types
por: Gion, Yuka, et al.
Publicado: (2017)

Clinicopathologic Characterization of Diffuse-Large-B-Cell Lymphoma with an Associated Serum Monoclonal IgM Component
por: Cox, M. Christina, et al.
Publicado: (2014)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

STAT3 Targets Suggest Mechanisms of Aggressive Tumorigenesis in Diffuse Large B-Cell Lymphoma
por: Hardee, Jennifer, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_53rgmningjnmrlr2lgd77eogut